Navigation Links
Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC

FARMINGDALE, N.Y., April 7 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, announced that it has sold its Ultrasonic Laboratory business for $3.5 million in cash to iSonix LLC. The Ultrasonic Laboratory business manufactures and markets scientific and industrial ultrasonic equipment and recorded approximately $4.6 million in revenue in Fiscal 2008.

Michael A. McManus, Jr., President and Chief Executive Officer, stated, "We are pleased to further strengthen our balance sheet with the additional $3.5 million in cash from the sale of a non-core business. We expect to use the proceeds to pay down some of our bank debt, increase our working capital and other general corporate purposes. We also believe the transaction speaks to the underlying value of our businesses that we believe has not been reflected in our market capitalization today. Most importantly, this transaction also emphasizes our commitment to continue our growth initiatives and become a focused medical device company."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Cameron Associates, Inc.
    Kevin McGrath

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
2. Misonix Announces New Sales Agency Agreement for Eastern Europe
3. Misonix Announces New Distribution Agreement for Israel
4. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
5. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
6. Misonix Announces New HIFU Distribution Agreement for Italy
7. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
8. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
9. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
10. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
11. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
(Date:11/29/2015)... Aliso Viejo, CA (PRWEB) , ... November 29, ... ... is an all new and unique analog distortion effect tool designed specially for ... to their footage, and create limiltess looks with the easy-to-use modification controls. Destoying ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices ... inventors, one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, ... to save the expense of having to replace NuvaRings more often than necessary. As ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology: